Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
January 5, 1999
Assignee:
Immunex Corporation
Inventors:
Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
Abstract: Antagonists of mammalian interleukin-15 ("IL-15") are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R.alpha.-subunit and that are incapable of transducing a signal through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the .beta.- or .gamma.-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
Type:
Grant
Filed:
February 22, 1995
Date of Patent:
August 18, 1998
Inventors:
Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
Abstract: Mammalian Interleukin-4 receptor proteins find use in inhibiting biological activities of IL-4. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
June 16, 1998
Assignee:
Immunex Corporation
Inventors:
Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
Abstract: Methods of enhancing a mammal's immune response to a vaccine antigen are disclosed. Interleukin-15 can be used as a vaccine adjuvant to enhance or potentiate the immune response to a vaccine. Compositions comprising an immunogenic amount of vaccine antigen and an immunogenicity-augmenting amount of IL-15 are also provided by the invention. IL-15 can be used alone in the invention or in concurrent or sequential combination with additional vaccine adjuvants.
Type:
Grant
Filed:
July 19, 1995
Date of Patent:
May 5, 1998
Assignee:
Immunex Corporation
Inventors:
Kenneth H. Grabstein, Michael B. Widmer
Abstract: Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Type:
Grant
Filed:
November 29, 1994
Date of Patent:
January 27, 1998
Assignee:
Immunex Corporation
Inventors:
Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed.
Abstract: A method for detecting anti-Leishmania parasite antibodies to a 230 kDa antigen present in Leishmania chagasi and Leishmania donovani is disclosed which comprises obtaining a sample from an individual, contacting the sample with a recombinant K39 repeat unit antigen comprising the amino acid sequence as shown in SEQ ID NO:3, and detecting the presence of anti-Leishmania parasite antibodies in the sample which bind to the recombinant K39 repeat unit antigen.
Abstract: Tumor necrosis factor receptor proteins, DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
Type:
Grant
Filed:
May 10, 1990
Date of Patent:
March 7, 1995
Assignee:
Immunex Corporation
Inventors:
Craig A. Smith, Raymond G. Goodwin, M. Patricia Beckmann
Abstract: Isolated viral proteins, and pharmaceutical compositions made therefrom, are disclosed which are capable of binding to Tumor Necrosis Factor, thereby functioning as Tumor Necrosis Factor antagonists. Also disclosed are processes for preparing isolated viral protein cytokine antagonists.
Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
Type:
Grant
Filed:
July 12, 1993
Date of Patent:
September 27, 1994
Assignee:
Immunex Corporation
Inventors:
John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
Abstract: The present invention provides an isolated DNA sequence encoding soluble and membrane bound forms of a mammalian IgA Fc receptor, as well as recombinant expression vectors and host cells suitable for expressing the protein.
Abstract: Substantially purified and homogeneous soluble human interleukin-1 receptor (shuIL-1R) proteins, DNA encoding the shuIL-1R proteins and pharmaceutical compositions containing the shuIL-1R proteins are described.
Type:
Grant
Filed:
January 14, 1992
Date of Patent:
June 7, 1994
Assignee:
Immunex Corporation
Inventors:
Steven K. Dower, Carl J. March, John Sims, David L. Urdal
Abstract: Ligand reagents are disclosed which consist essentially of recombinant hyperglycosylated cytokines, expressed in yeast, which are purified and conjugated to various functional moieties, for example, biotin groups, via oligosaccharide residues. Methods of using such ligand reagents are also disclosed.
Abstract: Mammalian Interleukin-1 receptor proteins (IL-1Rs), DNAs and expression vectors encoding mammalian IL-1Rs, and processes for producing mammalian IL-1Rs as products of cell culture, including recombinant systems, are disclosed.
Type:
Grant
Filed:
March 1, 1993
Date of Patent:
March 22, 1994
Assignee:
Immunex Corporation
Inventors:
Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal
Abstract: Leukemia inhibitory factor receptor (LIF-R) proteins, DNAs and expression vectors encoding LIF-R, and processes for producing LIF-R as products of recombinant cell culture, are disclosed.
Abstract: There is disclosed an immunotherapy method for treating an individual with cancer or a viral infection comprising obtaining lymphoid cells previously exposed to a specific antigen, culturing the lymphoid cells ex vivo in a culture medium containing an effective amount of an IL-7 polypeptide or a functional derivative thereof to induce CTL activity in the lymphoid cells and administering the lymphoid cells having CTL activity for cells displaying the specific antigen to an individual.
Abstract: Soluble human Interleukin-1 receptor proteins (shuIL-1Rs) and methods of using shuIL-1Rs to suppress immune or inflamatory responses in a mammal.
Type:
Grant
Filed:
June 14, 1993
Date of Patent:
February 11, 1997
Assignee:
Immunex Corporation
Inventors:
Steven K. Dower, Carl J. March, John E. Sims, David L. Urdal